{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:18:22Z","timestamp":1777731502922,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.clinthera.2006.03.001","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T21:13:22Z","timestamp":1149714802000},"page":"332-339","source":"Crossref","is-referenced-by-count":27,"title":["A 6-week, double-masked, paralle-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%\/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension"],"prefix":"10.1016","volume":"28","author":[{"given":"Wendy A.","family":"Franks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean P.","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prin","family":"Rojanapongpun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.03.001_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials","volume":"112","author":"Van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2006.03.001_bib2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-3565(24)36681-9","article-title":"FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study","volume":"281","author":"Griffin","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2006.03.001_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and otherPG receptors in cultured cells","volume":"19","author":"Sharif","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.001_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/108076803322473006","article-title":"Human ciliary muscle cell responses to FP-class prostaglandin analogs: Phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation","volume":"19","author":"Sharif","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.001_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1167\/iovs.02-0323","article-title":"Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues","volume":"44","author":"Sharif","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2006.03.001_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-4835(89)90049-3","article-title":"Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey","volume":"49","author":"Gabelt","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.clinthera.2006.03.001_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgusmonkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.clinthera.2006.03.001_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archopht.1987.01060080114039","article-title":"Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha","volume":"105","author":"Crawford","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib9","first-page":"519","article-title":"Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans","volume":"23","author":"Camras","year":"1995","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"10.1016\/j.clinthera.2006.03.001_bib10","series-title":"Poster presented at: American Glaucoma Society 15th Annual Meeting","article-title":"Effect of travoprost on diurnal and nocturnal aqueous humor dynamics in patients with ocular hypertension and glaucoma","author":"Toris","year":"2005"},{"key":"10.1016\/j.clinthera.2006.03.001_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1350-9462(99)00015-4","article-title":"The regulation of trabecular meshwork and ciliary muscle contractility","volume":"19","author":"Wiederholt","year":"2000","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2006.03.001_bib12","first-page":"2772","article-title":"Prostaglandins increase matrix metal Ioproteinase release from human ciliary smooth muscle cells","volume":"38","author":"Weinreb","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2006.03.001_bib13","first-page":"2461","article-title":"Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle","volume":"36","author":"Poser","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2006.03.001_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02742255","article-title":"The effect of Prostaglandins on the isolated internal muscles of mammalian eye, including man","volume":"42","author":"Alphen","year":"1977","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","article-title":"The mechanism of timolol in lowering intraocular pressure. In the normal eye","volume":"96","author":"Coakes","year":"1978","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/108076802760116142","article-title":"Adenylyl cyclase activity mediated by beta-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells","volume":"18","author":"Crider","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.03.001_bib17","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","article-title":"Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2006.03.001_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067008","article-title":"Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma","volume":"95","author":"Zimmerman","year":"1977","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0149-2918(04)90008-2","article-title":"Comparison ofthe diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure","volume":"26","author":"Dubiner","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.03.001_bib20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glauco ma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/112067210401400509","article-title":"Intraocular pressure lowering efficacy of travo prost","volume":"14","author":"Przydryga","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib22","series-title":"Ethical Principles for Medical Research Involving Human Subjects","author":"World Medical Association Declaration of Helsinki","year":"2006"},{"key":"10.1016\/j.clinthera.2006.03.001_bib23","series-title":"Travatan","year":"2004"},{"key":"10.1016\/j.clinthera.2006.03.001_bib24","series-title":"Xalcom","year":"2005"},{"key":"10.1016\/j.clinthera.2006.03.001_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0002-9394(02)01460-5","article-title":"A comparison of once-daily morning vs evening dosing of concomitant latanoprost\/timolol","volume":"133","author":"Konstas","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib26","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archopht.123.7.898","article-title":"Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy","volume":"123","author":"Konstas","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjo.2003.018234","article-title":"A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients withopen angle glaucoma and ocular hypertension","volume":"88","author":"Diestelhorst","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004170050124","article-title":"Comparison of two fixed combinations of latanoprost and timolol in open angle glaucoma","volume":"236","author":"Diestelhorst","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9394(86)90532-5","article-title":"Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978\u20131985","volume":"102","author":"Nelson","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","article-title":"Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol.Scandinavian Latanoprost Study Group","volume":"102","author":"Alm","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2006.03.001_bib31","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0140-6736(95)90116-7","article-title":"Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents","volume":"345","author":"Diggory","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.03.001_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/bjo.80.1.85","article-title":"Medical treatment of glaucoma\u2014a reappraisal of the risks","volume":"80","author":"Diggory","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2006.03.001_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/112067210301300304","article-title":"Peripheral vasospasm and nocturnal blood pressure dipping-two distinct risk factors for glaucomatous damage?","volume":"13","author":"Pache","year":"2003","journal-title":"Eur J Ophthalmol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180600066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180600066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:48:12Z","timestamp":1736408892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180600066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S014929180600066X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.03.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}